



Appian Labs Announces Development and Commercial License Agreement with Capsugel for the AppiForm™ Modular Release System

Austin, TX -- November 17, 2009 -- Appian Labs, LLC, a biopharmaceutical company specializing in advanced therapeutic design and delivery, has announced an exclusive Development and Commercial License Agreement for the company's AppiForm™ Modular Release System with Capsugel, the world's leading provider of dosage form solutions to the pharmaceutical and related healthcare industries. The agreement provides for Capsugel to utilize the AppiForm Modular Release System for customizable drug delivery profiles.

Under the terms of the agreement, Capsugel will have exclusive rights to the AppiForm Modular Release System technology that enables custom-matching of desired release kinetics. The AppiForm platform formulations can be used to develop oral dosage forms with unique release profiles that include periods of delayed action, controlled decreasing rate or even increasing rate of release as well as zero order delivery. The unique design of the AppiForm system allows for release of several drugs or beneficial agents in sequential mode at constant or decreasing rates.

Appian Labs President Brian Windsor said, "We are extremely pleased to partner with Capsugel in exclusive development. The types of release profiles afforded by the AppiForm system are increasingly in demand globally. As both a leader and innovator in pharmaceutical products and services, Capsugel is a perfect fit for developing and launching the AppiForm technology."

Dr. Keith Hutchison, Vice President of Research and Development for Capsugel, remarked, "This agreement with Appian Labs supports our strategy to offer a wide range of oral dosage form solutions to our healthcare customers around the world. The drug delivery performance of the AppiForm technology is impressive. It will allow our customers to achieve customized release profiles for their API's, and at the same time to bring new products to market by taking advantage of Capsugel's manufacturing know-how."

About Capsugel

Capsugel's customers span the globe and include all major healthcare markets: Pharmaceutical, OTC Consumer, and Health and Nutrition. Long recognized as an industry leader, Capsugel's focus is to help customers formulate new products, as well as enhance existing product lines, and bring new products to market faster.

--more--

Page 2 of 2

Appian Labs Announces Development and Commercial License Agreement with Capsugel for the AppiForm™ Modular Release System

In addition to capsule products, Capsugel offers a comprehensive product and service array for drug formulations in liquid form as part of its Licaps® Drug Delivery System.

With a focus on innovation, recent product launches include the CFS 1500 C Liquid Filling and Sealing Machine and the Xcelodose® S Precision Powder Micro-filling System. Both utilize advanced technology that can better enable R&D scientists to accelerate the pace of drug development.

Capsugel is a division of Pfizer Inc., a Fortune 100 global pharmaceutical company, and has numerous global locations to support customers on every major continent. For more information, visit the company website at www.capsugel.com

About Appian Labs

Appian Labs, LLC is a biopharmaceutical company specializing in advanced therapeutic design. The company is focused on providing drug delivery and design solutions for biotech, pharmaceutical and life science companies worldwide. Appian Labs provides solutions for a number of drug delivery problems, including poor bioavailability or solubility, dose timing, toxicity and many others. The company designs tailor-made solutions to current drug delivery problems as well as innovative new formulations for the next generation of pharmaceuticals. Appian Labs is funded and managed by life sciences investment and management company, Emergent Technologies, Inc. (ETI). For more information, visit the company website www.appianlabs.com

###

Media Contact:

Sandra Oak
Nsight Public Relations
321-591-1508
soak@nsightpr.com